Depleting IL1R2+ Tumor-Infiltrating Regulatory T Cells with an ADCC-Prone Nanobody Construct Boosts the Efficacy of Anti-PD-1 Immunotherapy.
Arnouk SM, Kancheva D, Van Damme H, Courtoy GE, Mora Barthelmess R, Van Craenenbroeck J, Lebegge E, Elkrim Y, Assaf N, Heremans Y, Murgaski A, De Groof TWM, Clappaert E, Debraekeleer A, Brughmans J, Blancke G, Kiss M, Forsyth R, Waelput W, Boon L, Devoogdt N, Stortelers C, van Boxel N, Dombrecht B, Vereecke L, Vincke C, Raes G, Laoui D, Van Ginderachter JA.
Arnouk SM, et al. Among authors: raes g.
Cancer Res. 2025 Dec 1;85(23):4681-4700. doi: 10.1158/0008-5472.CAN-24-3095.
Cancer Res. 2025.
PMID: 40960523
Free PMC article.